Bausch Health Companies Inc. Overview
Pro stress-test →Bausch Health Companies Inc. is a global, diversified pharmaceutical company that develops, manufactures and markets health care products across multiple therapeutic areas. The company operates in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics and eye health. The company has shown strong recent momentum with revenue up 6.8% year-over-year in Q3 with EPS beating estimates and continues strategic debt refinancing.
Strategic Profile
Pro stress-test →Bausch Health operates through five business segments—Salix (gastroenterology), International, Solta Medical (aesthetics), Diversified (specialty pharma), and Bausch + Lomb (eye health). The company has undertaken exchange offers to refinance existing senior secured notes and has issued new 10.00% Senior Secured Notes due 2032, signaling focus on deleveraging. The company completed the acquisition of DURECT Corporation through a tender offer and merger, making DURECT a wholly owned subsidiary.
Competitive Landscape
Pro stress-test →Bausch Health competes in highly fragmented pharmaceutical and medical device markets across multiple therapeutic areas. Key competitors include large integrated pharma companies (Johnson & Johnson in eye care/aesthetics, AbbVie in gastroenterology), specialty pharma firms, and generic manufacturers. The company differentiates through its focused portfolio approach—particularly strong in gastroenterology (Salix), aesthetics (Solta), and eye health (Bausch + Lomb), though Bausch + Lomb operates as a separate public company post-spin-off considerations.
Industry Context
Bausch Health Companies Inc. operates in Specialty Pharmaceuticals & Medical Devices.
Key facts
Founded: 1994 · Headquarters: Laval, Canada · Revenue: $10.27B (2025 FY) · Market cap: $3.26B CAD